Amgen and Allergan submit biosimilar MAA to EMA for ABP 215, a biosimilar to bevacizumab
Amgen and Allergan announced submission of a Marketing Authorization Application to the EMA for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA.
December 02, 2016